The antigenic structure of the HIV gp120 envelope glycoprotein

Author(s): Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al.

Abstract

The human immunodeficiency virus HIV-1 establishes persistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS). The HIV-1 envelope glycoproteins, gp120 and gp41, are assembled into a trimeric complex that mediates virus entry into target cells1. HIV-1 entry depends on the sequential interaction of the gp120 exterior envelope glycoprotein with the receptors on the cell, CD4 and members of the chemokine receptor family2,3,4. The gp120 glycoprotein, which can be shed from the envelope complex, elicits both virus-neutralizing and non-neutralizing antibodies during natural infection. Antibodies that lack neutralizing activity are often directed against the gp120 regions that are occluded on the assembled trimer and which are exposed only upon shedding5,6. Neutralizing antibodies, by contrast, must access the functional envelope glycoprotein complex7 and typically recognize conserved or variable epitopes near the receptor-binding regions8,9,10,11. Here we describe the spatial organization of conserved neutralization epitopes on gp120, using epitope maps in conjunction with the X-ray crystal structure of a ternary complex that includes a gp120 core, CD4 and a neutralizing antibody12. A large fraction of the predicted accessible surface of gp120 in the trimer is composed of variable, heavily glycosylated core and loop structures that surround the receptor-binding regions. Understanding the structural basis for the ability of HIV-1 to evade the humoral immune response should assist in the design of a vaccine.

Similar Articles

Trial, error and breakthrough: A review of HIV vaccine development

Author(s): Barry SM, Mena Lora AJ, Novak RM

Cell responses to HIV-1 infection and vaccination: pathways to preventing infection

Author(s): Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD

Crystal structure of a soluble cleaved HIV-1 envelope trimer

Author(s): Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al.

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer

Author(s): Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al.

Gene therapy as a vaccine for HIV-1

Author(s): Berkhout B, Sanders RW

Antibody gene transfer for HIV immunoprophylaxis

Author(s): Balazs AB, West AP

Rapamycin-regulated control of antiangiogenic tumor therapy following raav-mediated gene transfer

Author(s): Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, et al.

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation

Author(s): Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al.

Novel targets for antiretroviral therapy

Author(s): Dau B, Holodniy M.

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env

Author(s): Scharf L, Wang H, Gao H, Chen S, McDowall AW, et al.